Use Of Oral Tenofovir-Based PrEP For HIV Prevention In HBV-Endemic Countries, High-Risk Populations May Decrease Number Of HIV And HBV Coinfections, Researchers Say

Healio (8/29, Stulpin) reports, “The use of oral tenofovir-based PrEP for HIV prevention in hepatitis B-endemic countries and in high-risk populations could ‘markedly decrease’ the number of HIV and HBV coinfections, researchers found in a review.” But, “...